Polatuzumab vedotin联合利妥昔单抗治疗弥漫大B细胞淋巴瘤的分子学依据
本研究利用Pola难治性细胞探讨Polatuzumab vedotin(Pola)联合利妥昔单抗(Rit)的分子机制。Pola处理增加CD20表达及Rit诱导的补体依赖性细胞毒作用(CDC)敏感性,该效应依赖AKT和ERK磷酸化;在Pola难治性移植瘤中Pola亦增加CD20表达并显著增强Rit联合的抗肿瘤活性,为Pola联合Rit提供新依据。
要点
- Pola处理增加Pola难治性细胞的CD20表达和对Rit诱导CDC的敏感性。
- Pola诱导的CD20上调和CDC增敏依赖AKT和ERK的磷酸化。
- Pola在Pola难治性移植瘤中增加CD20表达并显著增强Rit联合抗肿瘤活性。
核心结论
- Pola联合Rit的分子学依据在于Pola通过AKT和ERK磷酸化上调CD20并增强Rit诱导的CDC敏感性,在Pola难治性移植瘤中联合Rit显著增强抗肿瘤活性。
研究设计与样本
- 基础研究,使用Pola难治性细胞和Pola难治性移植瘤模型,未报告样本量。
主要发现
- Pola处理在多种Pola难治性细胞中增加CD20表达和对Rit诱导CDC的敏感性。
- AKT和MEK特异性抑制剂均减弱Pola诱导的CD20增加和CDC敏感性增强,提示这些磷酸化事件为该联合疗效所需。
- 抗CD79b抗体增加AKT磷酸化但抑制ERK磷酸化;MMAE增强ERK磷酸化但轻度减弱AKT磷酸化。
- Pola在Pola难治性移植瘤中增加CD20表达,与Rit联合显著增强抗肿瘤活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polatuzumab vedotin (Pola) is an antibody-drug conjugate that targets the B-cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is approved in combination with bendamustine and rituximab (Rit) for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Understanding the molecular basis of Pola combination therapy with Rit, the key component for the treatment of DLBCL, is important to establish the effective treatment strategies against r/r DLBCL. Here, we examined the rationale for the combination of Pola with Rit using Pola-refractory cells. We found that treatment with Pola increased CD20 expression and sensitivity to Rit-induced complement-dependent cytotoxicity (CDC) in several Pola-refractory cells. Pola treatment increased phosphorylation of AKT and ERK and both AKT- and MEK-specific inhibitors attenuated the Pola-induced increase of CD20 and CDC sensitivity, suggesting that these phosphorylation events were required for this combination efficacy. It was revealed that anti-CD79b antibody increased the phosphorylation of AKT but inhibited the phosphorylation of ERK. In contrast, MMAE potentiated phosphorylation of ERK but slightly attenuated the phosphorylation of AKT. Pola also increased CD20 expression on Pola-refractory xenografted tumours and significantly enhanced antitumour activity in combination with Rit. In conclusion, these results could provide a novel rationale for the combination of Pola plus Rit.
引用
- Kawasaki N, Nishito Y, Yoshimura Y, et al. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. Br J Haematol. 2022. PMID: 35764309. doi:10.1111/bjh.18341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。